VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male or female of any race, at least 18 years of   │ Male or female of any race, at least 18 years of   │     100 │
│ age at Visit 1 Screening                           │ age at Visit 1 Screening                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has provided verbal and written informed consent   │ Has provided verbal and written informed consent   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be able and willing to follow instructions,        │ Be able and willing to follow instructions,        │     100 │
│ including participation in all study assessments   │ including participation in all study assessments   │         │
│ and visits                                         │ and visits                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently being treated for glaucoma using at      │ Currently being treated for glaucoma using at      │     100 │
│ least two medications, and be willing to continue  │ least two medications, and be willing to continue  │         │
│ on the same regime                                 │ on the same regime                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Suffers from at least two of the symptoms in the   │ Suffers from at least two of the symptoms in the   │     100 │
│ GLIA™ Glaucoma Medication Ocular Side Effect       │ GLIA™ Glaucoma Medication Ocular Side Effect       │         │
│ Symptoms Questionnaire at a severity of 2          │ Symptoms Questionnaire at a severity of 2          │         │
│ (moderate) or more                                 │ (moderate) or more                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If a woman of childbearing potential, have a       │ If a woman of childbearing potential, have a       │     100 │
│ negative urine pregnancy test at Visit 1 and be    │ negative urine pregnancy test at Visit 1 and be    │         │
│ using an adequate method of birth control          │ using an adequate method of birth control          │         │
│ throughout the study period                        │ throughout the study period                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Comorbidity with other severe or chronic eye       │ Comorbidity with other severe or chronic eye       │     100 │
│ conditions that in the judgment of the             │ conditions that in the judgment of the             │         │
│ investigator will interfere with study             │ investigator will interfere with study             │         │
│ assessments, such as corneal opacities and scars,  │ assessments, such as corneal opacities and scars,  │         │
│ dystrophies, epithelial scarring, infections,      │ dystrophies, epithelial scarring, infections,      │         │
│ blood clots, etc                                   │ blood clots, etc                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a condition or history that, in the opinion of │ Has a condition or history that, in the opinion of │     100 │
│ the investigator, may interfere significantly with │ the investigator, may interfere significantly with │         │
│ the subject's participation in the study           │ the subject's participation in the study           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A woman who is pregnant, nursing an infant, or     │ A woman who is pregnant, nursing an infant, or     │     100 │
│ planning a pregnancy                               │ planning a pregnancy                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a known adverse reaction and/or sensitivity to │ Has a known adverse reaction and/or sensitivity to │     100 │
│ the study drug or its components                   │ the study drug or its components                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Routine use (more than twice a week) of a          │ Routine use (more than twice a week) of a          │     100 │
│ chlorinated swimming pool                          │ chlorinated swimming pool                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwilling or unable to cease using the following   │ Unwilling or unable to cease using the following   │     100 │
│ medications during the study period: Topical       │ medications during the study period: Topical       │         │
│ ocular cyclosporine (e.g. Restasis®), anti-        │ ocular cyclosporine (e.g. Restasis®), anti-        │         │
│ histamines, antipsychotics, or eye gels            │ histamines, antipsychotics, or eye gels            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently enrolled in an investigational drug or   │ Currently enrolled in an investigational drug or   │     100 │
│ device study or have used an investigational drug  │ device study or have used an investigational drug  │         │
│ or device within 30 days prior to Visit 1          │ or device within 30 days prior to Visit 1          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Best corrected visual acuity (BCVA) at baseline    │ Best corrected visual acuity (BCVA) at baseline    │      99 │
│ \<20/200                                           │ <20/200                                            │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                             │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Routine use (more than twice a week) of a │      36 │
│                                   │ chlorinated swimming pool                 │         │
╘═══════════════════════════════════╧═══════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.66666666666667
OverAll Ratio: 97.33333333333334
